Validation of circulating tumor cells (CTC) detection techniques in patients with advanced solid tumors
- Conditions
- Advanced cancer10027655
- Registration Number
- NL-OMON33920
- Lead Sponsor
- Antoni van Leeuwenhoek Ziekenhuis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 200
Inclusion Criteria
Patients who are treated for advanced solid tumors;
Age of 18 years or older;
Able and willing to give written informed consent;
Able and willing to undergo veni-puncture;
Life expectancy of 3 months or more;
WHO performance status of 0, 1 or 2;
Exclusion Criteria
Any condition that may interfere with the study protocol
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Primary objective<br /><br>To optimize CTC detection assay sensitivity and specificity in different types<br /><br>of advanced solid tumors by comparison of enrichment techniques and expression<br /><br>level of a panel of selected marker genes.<br /><br><br /><br>Amendment:<br /><br>To compare CTC detection results of the FAST cytometry method to the qRT-PCR<br /><br>method.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Secondary objectives<br /><br>To determine intra-patient variation of CTC detection assay outcome.<br /><br>To assess inter-patient variation in CTC detection assay outcome.<br /><br>To determine which CTC detection assay is best suitable in the population of<br /><br>patients that participate in clinical trials.</p><br>